Please ensure Javascript is enabled for purposes of website accessibility

Drugstore Sales Droop in December

By Timothy M. Otte – Updated Apr 5, 2017 at 9:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Three major drug chains report soft sales for December. But there's always the flu to look forward to.

The three major drugstore chains reported December sales yesterday. Walgreen (NYSE: WAG), CVS (NYSE: CVS), and Rite Aid (NYSE: RAD) all bellied up to the bar with less-than-stellar sales results for the final month of 2007. How bad were they?

CVS and Walgreen hovered around 2% comps, while Rite Aid dipped slightly negative. The real story is comparing December numbers to prior trends, in this case, looking at the prior two months. All three companies were short of where they've been trending recently.

Comparable Sales

Company

Dec.

Nov.

Oct.

CVS

1.8%

4.4%

4.6%

Walgreen

2.6%

4.4%

6.9%

Rite Aid

(0.5%)

0.9%

0.4%

This is certainly not a disaster for these companies, although the financial press made a lot of noise about it, driving drugstore shares sharply lower. CVS is down nearly 6%, Walgreens has fallen about 9%, and Rite Aid has plunged 24% in the past few days. CVS even mentioned in its sales release that it expects full-year earnings near the top of previous guidance, and it ended the year posting 5.3% comps for 2007 over 2006. It's rare for these companies to give anything but the bare facts in sales releases.

Keep in mind that while retailers like Wal-Mart (NYSE: WMT) and Target (NYSE: TGT) benefit from holiday shopping in December, drugstore sales are driven by prescriptions, which bring traffic to the front end. And then there's flu season, which is getting off to a slow start. While this sounds like a blessing, drugstores do better when most of us are sniffling and sneezing.

My crystal ball hasn't given me any clues recently as to whether this will be a good or bad flu season, but it seems likely a normal amount of us will get to feeling under the weather at some point -- just a little later in the season. CVS and Walgreen in particular have been on a tear the past year or so. What looks like a few days of market overreaction may turn into a buying opportunity for savvy retail investors.  

For more views on health-related retail, check out:

Wal-Mart is an Inside Value pick. Check out the service free for 30 days.

Fool contributor Timothy M. Otte surveys the retail scene from Dallas. He welcomes comments on his articles, and owns shares of Wal-Mart, but none of the other companies mentioned in this article. The Fool's disclosure policy has never been sick a day in its life.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$32.69 (-0.43%) $0.14
CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$97.74 (-0.62%) $0.61
Rite Aid Corporation Stock Quote
Rite Aid Corporation
RAD
$6.50 (-7.28%) $0.51
Walmart Stock Quote
Walmart
WMT
$131.31 (0.96%) $1.25
Target Corporation Stock Quote
Target Corporation
TGT
$148.71 (-2.56%) $-3.90

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.